Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Inventory (2017 - 2025)

Ultragenyx Pharmaceutical has reported Inventory over the past 9 years, most recently at $52.0 million for Q4 2025.

  • Quarterly Inventory rose 15.56% to $52.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.0 million through Dec 2025, up 15.56% year-over-year, with the annual reading at $52.0 million for FY2025, 15.56% up from the prior year.
  • Inventory was $52.0 million for Q4 2025 at Ultragenyx Pharmaceutical, roughly flat from $52.2 million in the prior quarter.
  • Over five years, Inventory peaked at $52.2 million in Q3 2025 and troughed at $12.5 million in Q1 2021.
  • The 5-year median for Inventory is $30.0 million (2023), against an average of $31.4 million.
  • Year-over-year, Inventory increased 5.08% in 2021 and then soared 64.91% in 2022.
  • A 5-year view of Inventory shows it stood at $16.2 million in 2021, then soared by 64.91% to $26.8 million in 2022, then increased by 26.91% to $34.0 million in 2023, then soared by 32.47% to $45.0 million in 2024, then increased by 15.56% to $52.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Inventory are $52.0 million (Q4 2025), $52.2 million (Q3 2025), and $46.5 million (Q2 2025).